References

Bermudez-Silva, F.J., A. Serrano, F.J. Diaz-Molina, I. Sanchez Vera and P. Juan-Pico et al., 2006. Activation of cannabinoid CB1 receptors induced glucose intolerance in rats. Eur. J. Pharmcol., 531: 282-284.
CrossRef  |  

Bermudez-Silva, F.J., J. Suarez, E. Baixeras, N. Cobo and D. Bautista et al., 2008. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetology, 51: 476-487.
CrossRef  |  

Bonaventura, G., D. Cucco, D. Lipari, G.F. Spatola, M.L. Uzzo and V. Tessitore, 2007. Immunohistochemical expression of CB1 cannabinoids receptor in rat lung. Exp. Med. Rev., 1: 51-57.

Bonaventura, G., D. Cucco, G.F. Spatola, M.L. Uzzo and V. Tessitore, 2007. An immunohistochemical study on the CB1 receptor expression in rat salivary glands. Exp. Med. Rev., 1: 281-285.

Bonaventura, G., V. Tessitore, M.L. Uzzo and G.F. Spatola, 2005. Immunohistochemical distribution of orphanin FQ in the rat gastrointestinal apparatus and pancreas. Ital. J. Anat. Embryol., 110: 262-264.

Borrelli, F., G. Aviello, B. Romano, P. Orlando and R. Capasso et al., 2009. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med., 87: 1111-1121.
CrossRef  |  PubMed  |  Direct Link  |  

Calignano, A., G. La Rana, A. Makriyannis, S.Y. Lin, M. Beltramo and D. Piomelli, 1997. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol., 340: R7-8.
PubMed  |  Direct Link  |  

Cint, S., R. Maheis, C. Pico, E. Ceresi and A. Obrador et al., 2000. Secretory granules of endocrine and chief cells of human stomach mucosa contain leptin. Int. J. Obesity, 24: 789-793.
PubMed  |  Direct Link  |  

Colombo, G., R. Agabio, G. Diaz, C. Lobina, R. Reali and G.L. Gessa, 1998. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci., 63: PL113-PL117.
CrossRef  |  Direct Link  |  

Coruzzi, G., I.M. Adam, G. Coppelli, P. Frati and G. Soldani, 1999. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Arch. Pharmacol., 360: 715-718.
PubMed  |  Direct Link  |  

Cota, D. and S.C. Woods, 2005. The role of the endocannabinoid system in the regulation of energy homeostasis. Curr. Opin. Endocr. Diab., 12: 338-351.

Cota, D., 2007. CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev., 23: 507-517.
PubMed  |  Direct Link  |  

Cota, D., G. Marsicano, B. Lutz, V. Vicennati, G.K. Stalla, R. Pasquali and U. Pagotto, 2003. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord, 27: 289-301.
PubMed  |  Direct Link  |  

Cota, D., G. Marsicano, M. Tschop, Y. Grubler and C. Flachskamm et al., 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 112: 423-431.
CrossRef  |  

Cota, D., M.H. Tschop, T.L. Horvath and A.S. Levine, 2006. Cannabinoids, opioids and eating behavior: The molecular face of hedonism?. Brain Res. Rev., 51: 85-107.
PubMed  |  Direct Link  |  

Das, S.K., B.C. Paria, I. Chakraborty and S.K. Dey, 1995. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sci., 92: 4332-4336.
PubMed  |  Direct Link  |  

De Petrocellis, L., M.G. Cascio and V. Di Marzo, 2004. The endocannabinoid system: A general view and latest additions. Br. J. Pharmacol., 141: 765-774.
CrossRef  |  Direct Link  |  

Despres, J.P., A. Golay and L. Sjostrom, 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med., 353: 2121-2134.
Direct Link  |  

Di Marzo, L., T. Bisogno and L. De Petrocellis, 2000. Endocannabinoids: New targets for drug development. Curr. Pharm. Des., 6: 1361-1380.
PubMed  |  Direct Link  |  

Di Marzo, V. and I. Matias, 2005. Endocannabinoid control of food intake and energy balance. Nat. Neurosci., 8: 585-589.
CrossRef  |  Direct Link  |  

Di Marzo, V., M. Bifulco and L. De Petrocellis, 2004. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discovery, 3: 771-784.
CrossRef  |  

Di Marzo, V., R. Capasso, I. Matias, G. Aviello and S. Petrosino et al., 2008. The role of endocannabinoids in the regulation of gastric emptying: Alterations in mice fed a high-fat diet. Br. J. Pharmcol., 153: 1272-1280.
CrossRef  |  Direct Link  |  

Di Marzo, V., S.K. Goparaju, L. Wang, J. Liu and S. Batkai et al., 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410: 822-825.
PubMed  |  Direct Link  |  

Di Sabatino, A., N. Battista, P. Biancheri, C. Rapino and L. Rovedatti et al., 2011. The endogenous cannabinoid system in the gut of patientswith inflammatory bowel disease. Mucosal. Immunol., 4: 574-583.
CrossRef  |  Direct Link  |  

Elmquist, J.K., C.F. Elias and C.B. Saper, 1999. From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron, 22: 221-232.
PubMed  |  

Engeli, S., J. Bohnke, M. Feldpausch, K. Gorzelniak and J. Janke et al., 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 54: 2838-2843.
CrossRef  |  

Fernandez, J.R. and D.B. Allison, 2004. Rimonabant sanofi-synthelabo. Curr. Opin. Invest. Drugs, 5: 430-435.

Fox, P., P.G. Bain, S. Glickman, C. Carroll and J. Zajicek, 2004. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology, 62: 1105-1109.

Germano, M.P., V. D'Angelo, M.R. Mondello, S. Pergolizzi and F. Capasso et al., 2001. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Arch. Pharmacol., 363: 241-244.

Griffin, G., S.R. Fernando, R.A. Ross, N.G. McKay and M.L.J. Ashford et al., 1997. Evidence for the presence of CB₂-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol., 339: 53-61.
CrossRef  |  Direct Link  |  

Gye, M.C., H.H. Kang and H.J. Kang, 2005. Expression of cannabinoid receptor 1 in mouse testes. Arch. Androl., 51: 247-255.
CrossRef  |  Direct Link  |  

Hao, S., Y. Avraham, R. Mechoulam and E.M. Berry, 2000. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol., 392: 147-156.
CrossRef  |  Direct Link  |  

Howlett, A.C., F. Barth, T.I. Bonner, G. Cabral and P. Casellas et al., 2002. International Union of Pharmacology. XXV11. Classification of cannabinoid receptors. Pharmacol. Rev., 54: 161-202.
PubMed  |  Direct Link  |  

Izzo, A.A. and M. Camilleri, 2008. Emerging role of cannabinoids in gastrointestinal and liver diseases: Basic and clinical aspects. Gut, 57: 1140-1155.
CrossRef  |  Direct Link  |  

Izzo, A.A., F. Fezza, R. Capasso, T. Bisogno and L. Pinto et al., 2001. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134: 563-570.
CrossRef  |  PubMed  |  Direct Link  |  

Izzo, A.A., N. Mascolo, F. Borrelli and F. Capasso, 1999. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 359: 65-70.
CrossRef  |  PubMed  |  

Izzo, A.A., R. Capasso, G. Aviello, F. Borrelli and B. Romano et al., 2012. Inhibitory effect of cannabichonene, a major nonpsychotropic cannabinoid extracted from cannabis sativa, on inflammation induced hypermotility in mice. Bir. J. Pharmacol., 144: 1444-1460.
CrossRef  |  

Jamshidi, N. and D.A. Taylor, 2001. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol., 134: 1151-1154.
CrossRef  |  PubMed  |  

Juan-Pico, P., E. Fuentes, F.J. Bermudez-Silva, F. Diaz-Molina and C. Ripoll, F.R. de Fonseca and A. Nadal, 2006. Cannabinoid receptors regulate Ca²⁺ signals and insulin secretion in pancreatic β-cell. Cell Calcium, 39: 155-162.
CrossRef  |  

Kalra, S.P., M.G. Dube, S. Pu, B. Xu, T.L. Horvath and P.S. Kalra, 1999. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev., 20: 68-100.
CrossRef  |  

Katayama, K., N. Ueda, Y. Kurahashi, H. Suzuki, S. Yamamoto and I. Kato, 1997. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim. Biophys. Acta, 1347: 212-218.
CrossRef  |  PubMed  |  

Kirkham, T.C., 2003. Endogenous cannabinoids: A new target in the treatment of obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol., 284: 343-344.
PubMed  |  

Komorowski, J. and H. Stepien, 2007. The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans. Postepy Hig. Med. Dosw., 61: 99-105.
PubMed  |  

Kulkarni-Narla, A. and D.R. Brown, 2000. Localization of CB₁-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res., 302: 73-80.
CrossRef  |  

Liu, Y.L., I.P. Connoley, C.A. Wilson and M.J. Stock, 2005. Effects of the cannabinoid CB1 receptor antagonist R141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. Relat. Metab. Disord., 29: 183-187.

Matias, I., M.P. Gonthier, P. Orlando, V. Martiadis and L. de Petrocellis et al., 2006. Regulation, function and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab., 91: 3171-3180.
PubMed  |  Direct Link  |  

Matsuda, K., Y. Mikami, K. Takeda, S. Fukuyama and S. Egawa et al., 2005. The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis. Tohoku J. Exp. Med., 207: 99-107.
PubMed  |  

Matsuda, L.A., S.J. Lolait, M.J. Brownstein, A.C. Young and T.I. Bonner, 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346: 561-564.
CrossRef  |  Direct Link  |  

Mechoulam, R., S. Ben-Shabat, L. Hanus, M. Ligumsky and N.E. Kaminski et al., 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50: 83-90.
CrossRef  |  

Merck, 1899. Manual of the Materia Medica. Merck, New York, USA.

Michalski, C.W., T. Laukert, D. Sauliunaite, P. Pacher and F. Bergmann et al., 2007. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology, 132: 1968-1978.
CrossRef  |  

Munro, S., K.L. Thomas and M. Abu-Shaar, 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365: 61-65.
CrossRef  |  

Osei-Hyiaman, D., M. DePetrillo, P. Pacher, J. Liu and S. Radaeva et al., 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest, 115: 1298-1305.
CrossRef  |  PubMed  |  

Pagotto, U., V. Vicennati and R. Pasquali, 2007. The endocannabinoid system in the physiopathology of metabolic disorders. Horm. Res., 67: 186-190.
CrossRef  |  

Patton, G.C., C. Coffey, J.B. Carlin, L. Degenhardt, M. Lynskey and W. Hall, 2002. Cannabis use and mental health in young people: Cohort study. BMJ, 325: 1195-1198.
CrossRef  |  

Pertwee, R.G., 1999. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci., 65: 597-605.
PubMed  |  

Pertwee, R.G., 2000. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations relevant to future drug discovery and development. Exp. Opin. Invest. Drugs, 9: 1553-1571.
PubMed  |  

Pinto, L., R. Capasso, G. Di Carlo and A.A. Izzo, 2002. Endocannabinoids and the gut. Prostaglandins Leukot Essent Fatty Acids, 66: 333-341.
CrossRef  |  

Piomelli, D., 2003. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 4: 873-884.
CrossRef  |  Direct Link  |  

Plasse, T.F., R.W. Gorte, S.H. Krasnow, M. Lane, K.V. Shepard and R.G. Wadleigh, 1991. Recent clinical experience with dronabinol. Pharmacol. Biochem. Behav., 40: 695-700.
CrossRef  |  

Ravinet, T.C., M. Arnone, C. Delgorge, N. Gonalons, P. Keane, J.P. Maffrand and P. Soubrie, 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 284: 345-353.
PubMed  |  

Ruiz-Llorente, L., M.G. Sanchez, M.J. Carmena, J.C. Prieto, M. Sanchez-Chapado, A. Izquierdo and I. Diaz-Laviada, 2003. Expression of functionally active cannabinoid receptor CB₁ in the human prostate gland. Prostate, 54: 95-102.
CrossRef  |  PubMed  |  

Schicho, R. and M. Storr, 2011. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can. J. Gastroenetrol., 25: 377-383.
PubMed  |  

Shimabukuro, M., Y.T. Zhou, Y. Lee and R.H. Unger, 1998. Troglitazone lowers islet fat and restores β cell function of Zucker diabetic fatty rats. J. Biol. Chem., 273: 3547-3550.
PubMed  |  

Starowicz, K.M., L. Cristino, I. Matias, R. Capasso, A. Racioppi, A.A. Izzo and V. Di Marzo, 2008. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity, 16: 553-565.
CrossRef  |  PubMed  |  

Storr, M., A. Sibaev, G. Marsicano, B. Lutz, V. Schusdziarra, J.P. Timmermans and H.D. Allescher, 2004. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol., 286: 110-117.
PubMed  |  

Tessitore, V., G. Bonaventura, G.F. Spatola and L. Uzzo, 2005. Immunohistochemical expression orexin a andorexin type 2receptors in the rat gastrointestinal apparatus and endocrine pancreas. E. J. H., 49: 1-19.

Tessitore, V., M.L. Uzzo, G.F. Spatola, D. Cucco and G. Bonaventura, 2006. Immunohistochemical studies on leptin, grelin, orexin A, orphanin FQ and endocannabinoids expression in the stomach of lean and obese (fa/fa) Zucker rats. Proceedings of the 1st World Congress on Therapies against Obesity, May 18-19, 2006, Institut Pasteur Paris, France -.

Tessitore, V., M.L. Uzzo, G.F. Spatola, D. Cucco and G. Bonaventura, 2006. Immunohistochemical study and densitometric comparison on CB₁ receptor expression in the gastrointestinal tract and pancreas of obese (fa/fa) and lean Zucker rats. Ital. J. Anat Embriol., 111: 256-265.

Tharp, W.G., Y.H. Lee, R.L. Maple and R.E. Pratley, 2008. The cannabinoid CB₁ receptor is expressed in pancreatic δ-cells. Biochem. Biophys. Res. Communi., 372: 595-600.
CrossRef  |  PubMed  |  

Van Gaal, L.F., A.M. Rissanen, A.J. Scheen, O. Ziegler and S. Rossner, 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365: 1389-1397.
PubMed  |  

Vickers, P., L.J. Webster, A. Wyatt, C.T. Dourish and G.A. Kennett, 2003. Preferential effects of the cannabinoid CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacol., 167: 103-111.
PubMed  |  

Volicer, L., M. Stelly, J. Morris, J. McLaughlin and B.J. Volicer, 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry, 12: 913-919.
PubMed  |  

Wiley, J.L., J.J. Burston, D.C. Leggett, O.O. Alekseeva, R.K. Razdan, A. Mahadevan and B.R. Martin, 2005. CB₁ cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol., 145: 293-300.
CrossRef  |  PubMed  |  

Zajicek, J., P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn and A. Thompson, 2003. On behalf of the UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet, 362: 1517-1526.
Direct Link  |